Publications

5674 Results

Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405

Authors
W Zhang;F Battaglin;Y Yang;F-S Ou;F Innocenti;H Arai;S Soni;P Jayachandran;M Bertagnolli;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;CD Blanke;A Venook;O Kabbarah;J Millstein;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3580), poster 374; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

E1Q11: Engendering Reproductive health in Oncologic Survivorship (EROS)

Authors
A Patel;J-W Lee;H Zaren;E Radeke;R Lerner;J Fukui;D Makower;D Tamkus;K Rosland;W Adler;A Throckmorton;S Ghamande;D Cella;MJ Fisch;L Wagner
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 1519), poster 113; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Cancer Survivorship

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142

Authors
J Eads;P Catalano;G Fisher;D Rubin;A Iagaru;D Klimstra;B Konda;M Kwong;J Chan;A De Jesus-Acosta;T Halfdanarson;W Shaib;H Soares;S Hong;T Wong;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4020), poster #8; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2142

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide (P/E) with or without Atezolizumab (NSC#783608) in Patients (pts) with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;E Mayerson;E Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;S Das;J Starr;M Othus;YK Chae;R Kurzrock
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4179), poster 155a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors

Authors
K Ciombor;S Hong;C Eng;X Yao;M Thet Cho;YN You;P Das;A Chakravarthy;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3644), poster 430A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2201

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)

Authors
R Jensen;Y Zheng;M Atkins;B Chmielowski;A Tarhini;T-G Truong;D Divar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;S Lee;A Potosky;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9559), poster 152; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
CTSU/EA6134

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192.

Authors
G Gibney;S Lee;M Atkins;T Wong;J Guerriero;T Marron;G Cohen;T-G Truong;R Carvajal;B Snyder;M Farwell;J Kirkwood;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591), poster 183A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
EA6192

EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT): Trials in Progress

Authors
E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;C Gatsonis;D Zhen;D Li;L Wagner;M Simon;T Wong;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185), poster 157B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2186

A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202

Authors
A Bhatia;Y Flamand;J Johnson;J Ishizuka;F Duan;M Tang;V Karivedu;R Subramaniam;B Burtness
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6098), poster 89A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Authors
A Morgans;Y Chen;A Ferrari;P Tran;E Schaeffer;D Shevrin;R Szmulewitz;T Boike;T Dorff;G Liu;L Wagner;M Carducci
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster #98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary